Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov-Dec;35(6):3489-3493.
doi: 10.21873/invivo.12650.

The Association Between Hot Flashes and Renal Dysfunction After Androgen Deprivation Therapy With Radiotherapy in Japanese Patients With High-risk Prostate Cancer

Hiroshi Masuda  1 , Kosuke Mikami  2 , Kotaro Otsuka  2 , Kyokusin Hou  2 , Takahito Suyama  2 , Kazuhiro Araki  2 , Satoko Kojima  2 , Yukio Naya  2
Affiliations

The Association Between Hot Flashes and Renal Dysfunction After Androgen Deprivation Therapy With Radiotherapy in Japanese Patients With High-risk Prostate Cancer

Hiroshi Masuda et al. In Vivo. 2021 Nov-Dec.

Abstract

Background/aim: We investigated the changes in and characteristics of renal function in Japanese patients with high-risk prostate cancer (PCa) who underwent radiotherapy and long-term androgen deprivation therapy (ADT), including those seen after the ADT was discontinued.

Patients and methods: Among 60 patients who were pathologically diagnosed with PCa and received ADT for 24 months and radiotherapy, 36 patients who underwent treatment for stage B or C PCa were eligible. We assessed renal function using the estimated glomerular filtration rate (eGFR) and investigated the rate of change in the eGFR (ΔeGFR) during and after ADT. Univariate and multivariate logistic analyses were carried out to identify clinical factors that were significantly associated with renal dysfunction at 36 months.

Results: The incidence of renal dysfunction at 36 months was 75% (27/36). Multivariate analysis showed that the presence/absence of HF was an independent predictor of renal dysfunction at 36 months.

Conclusion: Renal function tended to recover after ADT was received for 24 months and subsequently discontinued. The presence/absence of HF represents new and meaningful information for patients receiving ADT, and high-risk PCa patients prior to ADT.

Keywords: ADT; High-risk prostate cancer; estimated glomerular filtration rate; hot flashes; renal dysfunction.

PubMed Disclaimer

Conflict of interest statement

The Authors state that they have no conflicts of interest relating to this study.

Figures

Figure 1
Figure 1. The rate of change in renal function during 24 months of androgen deprivation therapy (ADT) and after the discontinuation ADT (24-36 months) in patients with high-risk prostate cancer. There was no statistically significant change in the ΔeGFR during the ADT.
Figure 2
Figure 2. Comparison between the measured ΔeGFR and estimated ΔeGFR. The measured ΔeGFR tended to increase from 24 to 36 months.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA. 2005;294(2):238–244. doi: 10.1001/jama.294.2.238. - DOI - PubMed
    1. Shahinian VB, Kuo YF, Freeman JL, Orihuela E, Goodwin JS. Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer. 2005;103(8):1615–1624. doi: 10.1002/cncr.20955. - DOI - PubMed
    1. Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer. Eur Urol. 2013;64(1):159–166. doi: 10.1016/j.eururo.2012.04.035. - DOI - PMC - PubMed
    1. Ahmadi H, Daneshmand S. Androgen deprivation therapy for prostate cancer: long-term safety and patient outcomes. Patient Relat Outcome Meas. 2014;5:63–70. doi: 10.2147/PROM.S52788. - DOI - PMC - PubMed
    1. Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int. 2013;111(4):543–548. doi: 10.1111/j.1464-410X.2012.11774.x. - DOI - PubMed